ADRU - Invesco BLDRS Europe Select ADR Index Fund
| Previous Close | 19.80 |
| Open | 19.95 |
| Bid | 19.91 x 1000 |
| Ask | 19.95 x 800 |
| Day's Range | 19.95 - 19.95 |
| 52 Week Range | 18.35 - 22.24 |
| Volume | 4,200 |
| Avg. Volume | 746 |
| Net Assets | 11.42M |
| NAV | 19.86 |
| PE Ratio (TTM) | N/A |
| Yield | 3.77% |
| YTD Return | 6.27% |
| Beta (3Y Monthly) | 0.98 |
| Expense Ratio (net) | 0.30% |
| Inception Date | 2002-11-13 |
- Market Realist
Recommendations for GlaxoSmithKline on October 29
Wall Street analysts are estimating that GlaxoSmithKline will report revenues of ~8.02 billion pounds for the third quarter of 2018. GlaxoSmithKline stock has increased ~8.5% over the last 12 months and ~10.8% year-to-date. Analyst recommendations show a 12-month target price of $44.31 per share compared to its last price of $39.32 on October 26.
- Market Realist
What Analysts Recommend for Novartis after Q3 Earnings
Wall Street analysts estimate that Novartis will report revenues of $13.4 billion during the fourth quarter of 2018, a 4.0% increase in year-over-year revenues as compared to $12.9 billion during the fourth quarter of 2017. The earnings-per-share is estimated at $1.29 during the fourth quarter of 2018. Analysts estimate the net income margin to increase to 22.1% during the fourth quarter of 2018 as compared to 21.8% during the fourth quarter of 2017.
- Market Realist
How Novartis’s Innovative Medicines Business Performed in Q3
Novartis’s (NVS) Innovative Medicines business includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. The Innovative Medicines business contributed over 67.2% of the total revenues for Novartis and saw 6% growth in year-over-year (or YoY) revenues to ~$8.6 billion during the third quarter of 2018.
- Market Realist
A Closer Look at Novartis’s Innovative Medicines Segment
Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.
- Market Realist
Novartis ADR’s Performance and Revenue Estimates for Q3 2018
Headquartered in Basel, Switzerland, Novartis (NVS) specializes in research and development, manufacturing, and marketing of a broad range of healthcare products. The company’s three segments are Innovative Medicines, Sandoz, and Alcon. Sandoz is Novartis’s generics business, and Alcon is its eye care business.
- Market Realist
How GlaxoSmithKline’s Segments Performed
GlaxoSmithKline (GSK) has three business segments: the Pharmaceuticals segment, the Vaccines segment, and the Consumer Healthcare segment. We’ll discuss how the company’s segments performed in this article.
- Market Realist
Novartis to Divest Portions of Sandoz US to Aurobindo
Novartis (NVS) announced today, September 6, that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA for $0.9 billion in cash and $0.1 billion in potential earn-outs. The select portions include the Sandoz US dermatology business and the generic US oral solids business. The deal includes ~300 products and additional development programs that will be transferred from Sandoz’s US portfolio to Aurobindo.
- Market Realist
Novartis’s Sandoz in Q2 2018
Sandoz is Novartis’s (NVS) generics business and is a market leader in differentiated generics. Sandoz reported nearly flat revenues at ~$2.46 billion in Q2 2018 compared to $2.45 billion in the second quarter of 2017. Revenue growth was driven by a 2% favorable impact of foreign exchange, offset by a 2% decline in operating revenues.
- Market Realist
Novartis’s SOLAR-1 Trial Met Primary Endpoint
Novartis (NVS) announced on August 23 that its SOLAR-1 trial, a Phase 3 trial evaluating investigational drug BYL719 (alpelisib) in combination with fulvestrant, has met its primary endpoint.
